DBGen informs that it will cease its diagnostic activity for hereditary vision disorders as of February 1, 2024.
DBGen Ocular Genomics is a biotechnology company founded in January 2018 by scientists specialized in human genetics and based at the University of Barcelona. The main objectives of the DBGen team have been to achieve the highest scientific quality, constantly implement conceptual and methodological advances in the field of genetic diagnosis and offer direct and very close care to those affected, associations, clinical specialists and ophthalmological centers.
After many years of research and 6 years of business activity, DBGen has achieved diagnostic success comparable to that of the leading international companies in the sector, and much higher than the average of generalists diagnostic centers.
The DBGen team would like to underline and express its sincere gratitude for your encouragement, complicity and support throughout these years. Without them, DBGen would not have achieved the scientific milestones it set out to provide maximum care, help and guidance to patients and their families.
Barcelona, 15th January 2024
DBGen is a company highly specialized in the genetic testing of vision disorders.
Our raison d’être is to offer a high quality, reliable and affordable genetic diagnosis, which ensures clinical diagnosis and guides the patient towards emerging gene therapies for vision pathologies. DBGen team is firmly committed to contribute to precision medicine, promoting innovation and implementation of new diagnostic strategies based on the last conceptual and methodological advances.
Excellence in research and service
Decisive commitment to the patient’s quality of life
Genetic diagnosis applied to precision medicine
- 70-80% diagnostic yield.
- Interpretation of results by a team of passionate scientists and world-class professionals.
- Comprehensive and continuous follow up of the last advances and new pathological variants (bibliographic and database reviews).
- Actualization and optimization of Next Generation Sequencing (NGS) techniques and conceptual advances.
- Proximity with the patient, the ophthalmologist, patients’ associations and ophthalmological institutions.
- Accurate, comprehensive and easy to understand genetic reports in English, Spanish or Catalan.
- Customized approaches to diagnose challenging and atypical cases, including those previously unsolved in other testing labs.
The high professional standards of DBGen allows defining, confirming or reconsidering the clinical diagnosis.
- Availability of functional studies, on demand, to assess the pathogenicity of novel variants.
Re-analysis tests, on demand, to identify new genetic variants with clinical relevance to complement a previous diagnosis.
Last News
DBGen takes part in BIOSPAIN 2023
BIOSPAIN 2023, one of the largest European events aimed at biotechnology companies, is held this week in Barcelona (Fira de Barcelona – Montjuïc Av. Reina Mª Cristina). This congress brings
Applying massive sequencing to identify mutated genes in hereditary eye diseases
An agreement between the University of Barcelona spin-off DBGen Ocular Genomics and the company Novartis España will enable the genetic identification of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) in affected patients.
Strabismus as the first symptom of severe congenital disorders
In DBGen we offer a new panel «Panel of Syndromes that occur with Strabismus (Congenital Cranial Dysinnervation Disorders)» designed specifically for the genetic diagnosis of these pathologies. Strabismus